
Gennaro D'Amico

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7386584/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A model to predict survival in patients with end-stage liver disease. Hepatology, 2001, 33, 464-470.	3.6	4,112
2	Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. Journal of Hepatology, 2006, 44, 217-231.	1.8	2,459
3	Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology, 2003, 38, 599-612.	3.6	732
4	Clinical states of cirrhosis and competing risks. Journal of Hepatology, 2018, 68, 563-576.	1.8	302
5	Uncovered Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites: A Meta-Analysis. Gastroenterology, 2005, 129, 1282-1293.	0.6	209
6	Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: a cochrane meta-analysis. Gastroenterology, 2003, 124, 1277-1291.	0.6	208
7	Noninvasive markers of esophageal varices: Another round, not the last. Hepatology, 2004, 39, 30-34.	3.6	85
8	New concepts on the clinical course and stratification of compensated and decompensated cirrhosis. Hepatology International, 2018, 12, 34-43.	1.9	79
9	Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension. Hepatology, 2019, 69, 1287-1299.	3.6	45
10	The clinical course of cirrhosis. Population based studies and the need of personalized medicine. Journal of Hepatology, 2014, 60, 241-242.	1.8	36
11	Emergency sclerotherapy versus medical interventions for bleeding oesophageal varices in cirrhotic patients. , 2002, , CD002233.		23
12	Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology. Journal of Hepatology, 2021, 75, 1355-1366.	1.8	15
13	Ordinal Outcomes Are Superior to Binary Outcomes for Designing and Evaluating Clinical Trials in Compensated Cirrhosis. Hepatology, 2020, 72, 1029-1042.	3.6	14
14	The role of vasoactive drugs in the treatment of oesophageal varices. Expert Opinion on Pharmacotherapy, 2004, 5, 349-360.	0.9	13
15	Betaâ€blockers in 2016: Still the safest and most useful drugs for portal hypertension?. Hepatology, 2016, 63, 1771-1773.	3.6	11
16	Prognosis research and risk of bias. Internal and Emergency Medicine, 2016, 11, 251-260.	1.0	11
17	Prediction of Decompensation in Patients with Compensated Cirrhosis: Does Etiology Matter?. Current Hepatology Reports, 2019, 18, 144-156.	0.4	9
18	The role of vasoactive drugs in the treatment of oesophageal varices. Expert Opinion on Pharmacotherapy, 2004, 5, 349-60.	0.9	9

#	Article	IF	CITATIONS
19	Refining earlyâ€ <scp>TIPS</scp> criteria requires good quality prognostic studies. Liver International, 2018, 38, 412-414.	1.9	4
20	MELD calibration. American Journal of Transplantation, 2021, 21, 438-439.	2.6	2
21	Taking a risk-based approach to testing for liver disease in primary care, a step in the right direction. Journal of Hepatology, 2022, , .	1.8	1